How to buy Crinetics Pharmaceuticals stock (CRNX)

Crinetics Pharmaceuticals is a biotechnology business based in the US. Crinetics Pharmaceuticals shares (CRNX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $53.94 – an increase of 2.28% over the previous week. Crinetics Pharmaceuticals employs 290 staff and has a trailing 12-month revenue of around $1 million.

Our top picks for where to buy Crinetics Pharmaceuticals stock

Buy Crinetics Pharmaceuticals stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Crinetics Pharmaceuticals stock price (NASDAQ: CRNX)

Use our graph to track the performance of CRNX stocks over time.

Crinetics Pharmaceuticals shares at a glance

• Key figures

Information last updated 2024-12-18.

Latest market close	$53.94
52-week range	$33.67 - $62.53
50-day moving average more info button	$56.86
200-day moving average more info button	$50.42
Wall St. target price	$74.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-3.70

Is it a good time to buy Crinetics Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Crinetics Pharmaceuticals price performance over time

Historical closes compared with the close of $53.94 from 2024-12-24

1 week (2024-12-19)	2.28%
1 month (2024-11-26)	-4.99%
3 months (2024-09-26)	6.64%
6 months (2024-06-26)	27.85%

1 year (2023-12-26)	49.38%
2 years (2022-12-23)	222.99%
3 years (2021-12-23)	103.47%
5 years (2019-12-26)	126.35%

Crinetics Pharmaceuticals financials

Revenue TTM	$1 million
Gross profit TTM	$-125,488,000
Return on assets TTM	-24.29%
Return on equity TTM	-40.26%
Profit margin	0%
Book value	$10.30
Market Capitalization more info button	$4.8 billion

TTM: trailing 12 months

Crinetics Pharmaceuticals share dividends

We're not expecting Crinetics Pharmaceuticals to pay a dividend over the next 12 months.

Crinetics Pharmaceuticals share price volatility

Over the last 12 months, Crinetics Pharmaceuticals's shares have ranged in value from as little as $33.67 up to $62.53. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Crinetics Pharmaceuticals's is 0.619. This would suggest that Crinetics Pharmaceuticals's shares are less volatile than average (for this exchange).

Crinetics Pharmaceuticals overview

Crinetics Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Frequently asked questions

null
What percentage of Crinetics Pharmaceuticals is owned by insiders or institutions?
Currently 1.797% of Crinetics Pharmaceuticals shares are held by insiders and 94.685% by institutions. How many people work for Crinetics Pharmaceuticals?
Latest data suggests 290 work at Crinetics Pharmaceuticals. When does the fiscal year end for Crinetics Pharmaceuticals?
Crinetics Pharmaceuticals's fiscal year ends in December. Where is Crinetics Pharmaceuticals based?
Crinetics Pharmaceuticals's address is: 6055 Lusk Boulevard, San Diego, CA, United States, 92121 What is Crinetics Pharmaceuticals's ISIN number?
Crinetics Pharmaceuticals's international securities identification number is: US22663K1079 What is Crinetics Pharmaceuticals's CUSIP number?
Crinetics Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 22663K107